Global Central Nervous System
Global Central Nervous System

Central Nervous System Comprehensive Study by Drugs (Biologic, Non- Biologic), Disease (Infectious Diseases, Neurodegenerative Diseases, Autoimmune and Inflammatory Diseases, Genetic Disorders, Cancers, Trauma, Psychiatric Disorders, Others), Age Group (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2026

Central Nervous System Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Jan 2022 Edition 210 Pages 79 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Central Nervous System?
Central anxious machine (CNS) is a essential phase of the apprehensive device that consists the intelligence and the spinal cord. It integrates the acquired information, thereafter coordinating and controlling the things to do of all components of the body. However, CNS issues such as neurodegenerative diseases, autoimmune & inflammatory diseases, genetic disorders, cancers, and others have an effect on the shape and characteristic of the intelligence or spinal cord. Thus, CNS therapeutics are used to deal with these disorders.

The market study is broken down and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Central Nervous System market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Eli Lilly and Company (United States), Pfizer Inc (United States), Otsuka America Pharmaceutical, Inc (United States), Biogen (United States), AstraZeneca (United Kingdom), Novartis AG (Switzerland), Takeda (Japan), Merck & Co., Inc. (United States) and Teva Pharmaceutical Industries Ltd (Isarel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Johnson & Johnson Services, Inc. (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Central Nervous System market by Type, Application and Region.

On the basis of geography, the market of Central Nervous System has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Biologic will boost the Central Nervous System market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease, the sub-segment i.e. Infectious Diseases will boost the Central Nervous System market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Pediatric will boost the Central Nervous System market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2020, Innovent Biologics, Inc., a leading biopharmaceutical company, decalred the approval of its recombinant humanized anti-VEGF monoclonal antibody drug, BYVASDA by the National Medical Products Administration (NMPA) of China. The company reports that the central nervous system treatment solution is an effective therapeutic drug that can be used for treating glioblastoma patients.


Market Trend
  • Growing awareness regarding genetic regulatory similar to CNS

Market Drivers
  • Increasing Research and Development with Clinical Trials

Opportunities
  • Growing healthcare expenditure

Restraints
  • High cost of CNS tests and diagnostics

Challenges
  • Expansion of new drugs for disorders of the central nervous system


Key Target Audience
Manufacturers, Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Eli Lilly and Company (United States), Pfizer Inc (United States), Otsuka America Pharmaceutical, Inc (United States), Biogen (United States), AstraZeneca (United Kingdom), Novartis AG (Switzerland), Takeda (Japan), Merck & Co., Inc. (United States) and Teva Pharmaceutical Industries Ltd (Isarel) etc.

2. Can we have customized study for Central Nervous System Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Central Nervous System Market by 2026?
Analysts at AMA estimates Central Nervous System Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Drugs
  • Biologic
  • Non- Biologic

By Disease
  • Infectious Diseases
  • Neurodegenerative Diseases
  • Autoimmune and Inflammatory Diseases
  • Genetic Disorders
  • Cancers
  • Trauma
  • Psychiatric Disorders
  • Others

By Age Group
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Research and Development with Clinical Trials
    • 3.3. Market Challenges
      • 3.3.1. Expansion of new drugs for disorders of the central nervous system
    • 3.4. Market Trends
      • 3.4.1. Growing awareness regarding genetic regulatory similar to CNS
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Central Nervous System, by Drugs, Disease, Age Group and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Central Nervous System (Value)
      • 5.2.1. Global Central Nervous System by: Drugs (Value)
        • 5.2.1.1. Biologic
        • 5.2.1.2. Non- Biologic
      • 5.2.2. Global Central Nervous System by: Disease (Value)
        • 5.2.2.1. Infectious Diseases
        • 5.2.2.2. Neurodegenerative Diseases
        • 5.2.2.3. Autoimmune and Inflammatory Diseases
        • 5.2.2.4. Genetic Disorders
        • 5.2.2.5. Cancers
        • 5.2.2.6. Trauma
        • 5.2.2.7. Psychiatric Disorders
        • 5.2.2.8. Others
      • 5.2.3. Global Central Nervous System by: Age Group (Value)
        • 5.2.3.1. Pediatric
        • 5.2.3.2. Adult
        • 5.2.3.3. Geriatric
      • 5.2.4. Global Central Nervous System Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Central Nervous System: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka America Pharmaceutical, Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Ltd (Isarel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Central Nervous System Sale, by Drugs, Disease, Age Group and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Central Nervous System (Value)
      • 7.2.1. Global Central Nervous System by: Drugs (Value)
        • 7.2.1.1. Biologic
        • 7.2.1.2. Non- Biologic
      • 7.2.2. Global Central Nervous System by: Disease (Value)
        • 7.2.2.1. Infectious Diseases
        • 7.2.2.2. Neurodegenerative Diseases
        • 7.2.2.3. Autoimmune and Inflammatory Diseases
        • 7.2.2.4. Genetic Disorders
        • 7.2.2.5. Cancers
        • 7.2.2.6. Trauma
        • 7.2.2.7. Psychiatric Disorders
        • 7.2.2.8. Others
      • 7.2.3. Global Central Nervous System by: Age Group (Value)
        • 7.2.3.1. Pediatric
        • 7.2.3.2. Adult
        • 7.2.3.3. Geriatric
      • 7.2.4. Global Central Nervous System Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Central Nervous System: by Drugs(USD Million)
  • Table 2. Central Nervous System Biologic , by Region USD Million (2015-2020)
  • Table 3. Central Nervous System Non- Biologic , by Region USD Million (2015-2020)
  • Table 4. Central Nervous System: by Disease(USD Million)
  • Table 5. Central Nervous System Infectious Diseases , by Region USD Million (2015-2020)
  • Table 6. Central Nervous System Neurodegenerative Diseases , by Region USD Million (2015-2020)
  • Table 7. Central Nervous System Autoimmune and Inflammatory Diseases , by Region USD Million (2015-2020)
  • Table 8. Central Nervous System Genetic Disorders , by Region USD Million (2015-2020)
  • Table 9. Central Nervous System Cancers , by Region USD Million (2015-2020)
  • Table 10. Central Nervous System Trauma , by Region USD Million (2015-2020)
  • Table 11. Central Nervous System Psychiatric Disorders , by Region USD Million (2015-2020)
  • Table 12. Central Nervous System Others , by Region USD Million (2015-2020)
  • Table 13. Central Nervous System: by Age Group(USD Million)
  • Table 14. Central Nervous System Pediatric , by Region USD Million (2015-2020)
  • Table 15. Central Nervous System Adult , by Region USD Million (2015-2020)
  • Table 16. Central Nervous System Geriatric , by Region USD Million (2015-2020)
  • Table 17. South America Central Nervous System, by Country USD Million (2015-2020)
  • Table 18. South America Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 19. South America Central Nervous System, by Disease USD Million (2015-2020)
  • Table 20. South America Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 21. Brazil Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 22. Brazil Central Nervous System, by Disease USD Million (2015-2020)
  • Table 23. Brazil Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 24. Argentina Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 25. Argentina Central Nervous System, by Disease USD Million (2015-2020)
  • Table 26. Argentina Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 27. Rest of South America Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 28. Rest of South America Central Nervous System, by Disease USD Million (2015-2020)
  • Table 29. Rest of South America Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 30. Asia Pacific Central Nervous System, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 32. Asia Pacific Central Nervous System, by Disease USD Million (2015-2020)
  • Table 33. Asia Pacific Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 34. China Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 35. China Central Nervous System, by Disease USD Million (2015-2020)
  • Table 36. China Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 37. Japan Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 38. Japan Central Nervous System, by Disease USD Million (2015-2020)
  • Table 39. Japan Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 40. India Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 41. India Central Nervous System, by Disease USD Million (2015-2020)
  • Table 42. India Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 43. South Korea Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 44. South Korea Central Nervous System, by Disease USD Million (2015-2020)
  • Table 45. South Korea Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 46. Taiwan Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 47. Taiwan Central Nervous System, by Disease USD Million (2015-2020)
  • Table 48. Taiwan Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 49. Australia Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 50. Australia Central Nervous System, by Disease USD Million (2015-2020)
  • Table 51. Australia Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Central Nervous System, by Disease USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 55. Europe Central Nervous System, by Country USD Million (2015-2020)
  • Table 56. Europe Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 57. Europe Central Nervous System, by Disease USD Million (2015-2020)
  • Table 58. Europe Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 59. Germany Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 60. Germany Central Nervous System, by Disease USD Million (2015-2020)
  • Table 61. Germany Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 62. France Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 63. France Central Nervous System, by Disease USD Million (2015-2020)
  • Table 64. France Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 65. Italy Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 66. Italy Central Nervous System, by Disease USD Million (2015-2020)
  • Table 67. Italy Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 68. United Kingdom Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 69. United Kingdom Central Nervous System, by Disease USD Million (2015-2020)
  • Table 70. United Kingdom Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 71. Netherlands Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 72. Netherlands Central Nervous System, by Disease USD Million (2015-2020)
  • Table 73. Netherlands Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 74. Rest of Europe Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 75. Rest of Europe Central Nervous System, by Disease USD Million (2015-2020)
  • Table 76. Rest of Europe Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 77. MEA Central Nervous System, by Country USD Million (2015-2020)
  • Table 78. MEA Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 79. MEA Central Nervous System, by Disease USD Million (2015-2020)
  • Table 80. MEA Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 81. Middle East Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 82. Middle East Central Nervous System, by Disease USD Million (2015-2020)
  • Table 83. Middle East Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 84. Africa Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 85. Africa Central Nervous System, by Disease USD Million (2015-2020)
  • Table 86. Africa Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 87. North America Central Nervous System, by Country USD Million (2015-2020)
  • Table 88. North America Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 89. North America Central Nervous System, by Disease USD Million (2015-2020)
  • Table 90. North America Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 91. United States Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 92. United States Central Nervous System, by Disease USD Million (2015-2020)
  • Table 93. United States Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 94. Canada Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 95. Canada Central Nervous System, by Disease USD Million (2015-2020)
  • Table 96. Canada Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 97. Mexico Central Nervous System, by Drugs USD Million (2015-2020)
  • Table 98. Mexico Central Nervous System, by Disease USD Million (2015-2020)
  • Table 99. Mexico Central Nervous System, by Age Group USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Central Nervous System: by Drugs(USD Million)
  • Table 110. Central Nervous System Biologic , by Region USD Million (2021-2026)
  • Table 111. Central Nervous System Non- Biologic , by Region USD Million (2021-2026)
  • Table 112. Central Nervous System: by Disease(USD Million)
  • Table 113. Central Nervous System Infectious Diseases , by Region USD Million (2021-2026)
  • Table 114. Central Nervous System Neurodegenerative Diseases , by Region USD Million (2021-2026)
  • Table 115. Central Nervous System Autoimmune and Inflammatory Diseases , by Region USD Million (2021-2026)
  • Table 116. Central Nervous System Genetic Disorders , by Region USD Million (2021-2026)
  • Table 117. Central Nervous System Cancers , by Region USD Million (2021-2026)
  • Table 118. Central Nervous System Trauma , by Region USD Million (2021-2026)
  • Table 119. Central Nervous System Psychiatric Disorders , by Region USD Million (2021-2026)
  • Table 120. Central Nervous System Others , by Region USD Million (2021-2026)
  • Table 121. Central Nervous System: by Age Group(USD Million)
  • Table 122. Central Nervous System Pediatric , by Region USD Million (2021-2026)
  • Table 123. Central Nervous System Adult , by Region USD Million (2021-2026)
  • Table 124. Central Nervous System Geriatric , by Region USD Million (2021-2026)
  • Table 125. South America Central Nervous System, by Country USD Million (2021-2026)
  • Table 126. South America Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 127. South America Central Nervous System, by Disease USD Million (2021-2026)
  • Table 128. South America Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 129. Brazil Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 130. Brazil Central Nervous System, by Disease USD Million (2021-2026)
  • Table 131. Brazil Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 132. Argentina Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 133. Argentina Central Nervous System, by Disease USD Million (2021-2026)
  • Table 134. Argentina Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 135. Rest of South America Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 136. Rest of South America Central Nervous System, by Disease USD Million (2021-2026)
  • Table 137. Rest of South America Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 138. Asia Pacific Central Nervous System, by Country USD Million (2021-2026)
  • Table 139. Asia Pacific Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 140. Asia Pacific Central Nervous System, by Disease USD Million (2021-2026)
  • Table 141. Asia Pacific Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 142. China Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 143. China Central Nervous System, by Disease USD Million (2021-2026)
  • Table 144. China Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 145. Japan Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 146. Japan Central Nervous System, by Disease USD Million (2021-2026)
  • Table 147. Japan Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 148. India Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 149. India Central Nervous System, by Disease USD Million (2021-2026)
  • Table 150. India Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 151. South Korea Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 152. South Korea Central Nervous System, by Disease USD Million (2021-2026)
  • Table 153. South Korea Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 154. Taiwan Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 155. Taiwan Central Nervous System, by Disease USD Million (2021-2026)
  • Table 156. Taiwan Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 157. Australia Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 158. Australia Central Nervous System, by Disease USD Million (2021-2026)
  • Table 159. Australia Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Central Nervous System, by Disease USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 163. Europe Central Nervous System, by Country USD Million (2021-2026)
  • Table 164. Europe Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 165. Europe Central Nervous System, by Disease USD Million (2021-2026)
  • Table 166. Europe Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 167. Germany Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 168. Germany Central Nervous System, by Disease USD Million (2021-2026)
  • Table 169. Germany Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 170. France Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 171. France Central Nervous System, by Disease USD Million (2021-2026)
  • Table 172. France Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 173. Italy Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 174. Italy Central Nervous System, by Disease USD Million (2021-2026)
  • Table 175. Italy Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 176. United Kingdom Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 177. United Kingdom Central Nervous System, by Disease USD Million (2021-2026)
  • Table 178. United Kingdom Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 179. Netherlands Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 180. Netherlands Central Nervous System, by Disease USD Million (2021-2026)
  • Table 181. Netherlands Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 182. Rest of Europe Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 183. Rest of Europe Central Nervous System, by Disease USD Million (2021-2026)
  • Table 184. Rest of Europe Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 185. MEA Central Nervous System, by Country USD Million (2021-2026)
  • Table 186. MEA Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 187. MEA Central Nervous System, by Disease USD Million (2021-2026)
  • Table 188. MEA Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 189. Middle East Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 190. Middle East Central Nervous System, by Disease USD Million (2021-2026)
  • Table 191. Middle East Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 192. Africa Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 193. Africa Central Nervous System, by Disease USD Million (2021-2026)
  • Table 194. Africa Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 195. North America Central Nervous System, by Country USD Million (2021-2026)
  • Table 196. North America Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 197. North America Central Nervous System, by Disease USD Million (2021-2026)
  • Table 198. North America Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 199. United States Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 200. United States Central Nervous System, by Disease USD Million (2021-2026)
  • Table 201. United States Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 202. Canada Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 203. Canada Central Nervous System, by Disease USD Million (2021-2026)
  • Table 204. Canada Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 205. Mexico Central Nervous System, by Drugs USD Million (2021-2026)
  • Table 206. Mexico Central Nervous System, by Disease USD Million (2021-2026)
  • Table 207. Mexico Central Nervous System, by Age Group USD Million (2021-2026)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Central Nervous System: by Drugs USD Million (2015-2020)
  • Figure 5. Global Central Nervous System: by Disease USD Million (2015-2020)
  • Figure 6. Global Central Nervous System: by Age Group USD Million (2015-2020)
  • Figure 7. South America Central Nervous System Share (%), by Country
  • Figure 8. Asia Pacific Central Nervous System Share (%), by Country
  • Figure 9. Europe Central Nervous System Share (%), by Country
  • Figure 10. MEA Central Nervous System Share (%), by Country
  • Figure 11. North America Central Nervous System Share (%), by Country
  • Figure 12. Global Central Nervous System share by Players 2020 (%)
  • Figure 13. Global Central Nervous System share by Players (Top 3) 2020(%)
  • Figure 14. Global Central Nervous System share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 17. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 18. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 20. Otsuka America Pharmaceutical, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 21. Otsuka America Pharmaceutical, Inc (United States) Revenue: by Geography 2020
  • Figure 22. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 23. Biogen (United States) Revenue: by Geography 2020
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Takeda (Japan) Revenue: by Geography 2020
  • Figure 30. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Teva Pharmaceutical Industries Ltd (Isarel) Revenue, Net Income and Gross profit
  • Figure 33. Teva Pharmaceutical Industries Ltd (Isarel) Revenue: by Geography 2020
  • Figure 34. Global Central Nervous System: by Drugs USD Million (2021-2026)
  • Figure 35. Global Central Nervous System: by Disease USD Million (2021-2026)
  • Figure 36. Global Central Nervous System: by Age Group USD Million (2021-2026)
  • Figure 37. South America Central Nervous System Share (%), by Country
  • Figure 38. Asia Pacific Central Nervous System Share (%), by Country
  • Figure 39. Europe Central Nervous System Share (%), by Country
  • Figure 40. MEA Central Nervous System Share (%), by Country
  • Figure 41. North America Central Nervous System Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly and Company (United States)
  • Pfizer Inc (United States)
  • Otsuka America Pharmaceutical, Inc (United States)
  • Biogen (United States)
  • AstraZeneca (United Kingdom)
  • Novartis AG (Switzerland)
  • Takeda (Japan)
  • Merck & Co., Inc. (United States)
  • Teva Pharmaceutical Industries Ltd (Isarel)
Additional players considered in the study are as follows:
Johnson & Johnson Services, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation